Status:
TERMINATED
Evaluation of MRI for Prostate Cancer
Lead Sponsor:
Sheba Medical Center
Conditions:
Prostatic Neoplasms
Eligibility:
MALE
18-80 years
Brief Summary
The objective of this study is to evaluate imaging quality and correlation with histopathology in prostate cancer.
Detailed Description
The objective of this study is to evaluate of the potential of endorectal 3T MRI for the staging of prostate cancer before prostatectomy or recurrence of prostate cancer after prostatectomy
Eligibility Criteria
Inclusion
- Age of patients: up to 80 years.
- Men scheduled for radical prostatectomy due to prostate cancer or men post radical prostatectomy with suspicion of recurrence.
- Patients who are able and willing to give consent and able to have an MRI examination.
Exclusion
- Contraindications to MRI including: claustrophobia, weight over 120 kg, implanted ferromagnetic materials or foreign objects, and known intolerance to the MRI contrast agent (e.g. Gadolinium or Dotarem)
- Individuals who are not able or willing to tolerate the required prolonged stationary supine position during imaging (approximately 1 hr.)
- Any rectal pathology preventing probe insertion, (as active proctitis, active ulcerative colitis, fissure ani)
- Any spinal pathology that prohibits maintaining supine position for an hour
- Patients with documented myocardial infarction within one month of protocol entry, and patients with cardiac pacemakers
- Severe cerebrovascular disease (multiple CVA or CVA within 6 months)
Key Trial Info
Start Date :
November 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2011
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00930748
Start Date
November 1 2008
End Date
June 1 2011
Last Update
June 27 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sheba Medical Center
Ramat Gan, Israel